10.3389/fneur.2019.00710.s002
Anne-Catherine Bachoud-Lévi
Anne-Catherine
Bachoud-Lévi
Joaquim Ferreira
Joaquim
Ferreira
Renaud Massart
Renaud
Massart
Katia Youssov
Katia
Youssov
Anne Rosser
Anne
Rosser
Monica Busse
Monica
Busse
David Craufurd
David
Craufurd
Ralf Reilmann
Ralf
Reilmann
Giuseppe De Michele
Giuseppe
De Michele
Daniela Rae
Daniela
Rae
Ferdinando Squitieri
Ferdinando
Squitieri
Klaus Seppi
Klaus
Seppi
Charles Perrine
Charles
Perrine
Clarisse Scherer-Gagou
Clarisse
Scherer-Gagou
Olivier Audrey
Olivier
Audrey
Christophe Verny
Christophe
Verny
Jean-Marc Burgunder
Jean-Marc
Burgunder
Table_1_International Guidelines for the Treatment of Huntington's Disease.XLSX
Frontiers
2019
Huntington's disease
guidelines
treatment
care
clinical practice
2019-07-03 13:48:44
Dataset
https://frontiersin.figshare.com/articles/dataset/Table_1_International_Guidelines_for_the_Treatment_of_Huntington_s_Disease_XLSX/8540525
<p>The European Huntington's Disease Network (EHDN) commissioned an international task force to provide global evidence-based recommendations for everyday clinical practice for treatment of Huntington's disease (HD). The objectives of such guidelines are to standardize pharmacological, surgical and non-pharmacological treatment regimen and improve care and quality of life of patients. A formalized consensus method, adapted from the French Health Authority recommendations was used. First, national committees (French and English Experts) reviewed all studies published between 1965 and 2015 included dealing with HD symptoms classified in motor, cognitive, psychiatric, and somatic categories. Quality grades were attributed to these studies based on levels of scientific evidence. Provisional recommendations were formulated based on the strength and the accumulation of scientific evidence available. When evidence was not available, recommendations were framed based on professional agreement. A European Steering committee supervised the writing of the final recommendations through a consensus process involving two rounds of online questionnaire completion with international multidisciplinary HD health professionals. Patients' associations were invited to review the guidelines including the HD symptoms. Two hundred and nineteen statements were retained in the final guidelines. We suggest to use this adapted method associating evidence base–medicine and expert consensus to other rare diseases.</p>